🚨 New Publication Alert! Thank you to Bio-IT World for covering our latest research published in Springer Nature Communications. "Oral ENPP1 inhibitor designed using generative AI as next generation STING modulator for solid tumors" is now available. This work highlights the.

🚀 Our mission is to extend healthy productive longevity for everyone by transforming #drugdiscovery and development with generative #artificialintelligence, significantly reducing the time and cost to bring life-saving medications to patients. See our list of high quality

In our Phase 2a clinical trial for #Rentosertib, a generative AI–designed #TNIK inhibitor for idiopathic pulmonary fibrosis (#IPF), we not only advanced a novel first-in-class molecule but also generated a detailed pharmacokinetic profile that underscores its therapeutic

RT @biogerontology: Chronic GLP-1 inhibition will likely lead to side effects that will become noticeable later in life. This presents an o….

RT @AllThingsApx: The genAI template for virtual screening: generate → screen → enumerate → validate at scale. e.g. @InSilicoMeds's LEGION….

RT @Longevity_Inv: 🧬 Meet the Minds Merging AI & Longevity. From investment to innovation, AI is rapidly reshaping how we understand and ex….

🔬 Behind the Science: Understanding the TNIK Inhibitor Trial Design. The recent (June 2025) Springer Nature publication on #Rentosertib, an AI-discovered #TNIK inhibitor for idiopathic pulmonary fibrosis (#IPF), includes a compelling figure that outlines the trial architecture.

One of the best collaborations.The partnership began in 2020, after Syngenta approached Insilico Medicine at the highest levels. Both teams found the learning curve steep. Bogdan Zagribelnyy, Senior Researcher in Medicinal Chemistry and CADD, Insilico.

Thank you to HKIC for this incredible event coverage 📹

🔬 Thank You Chemistry World for Spotlighting the AI Revolution in #DrugDiscovery We’re honored to be featured in #ChemistryWorld’s recent article exploring whether AI-designed drugs are about to change pharma forever. The article highlights Insilico Medicine as a leader in.

Embracing the Cloud, the latest from @bioitworld All but one of the top 20 #pharma companies are building their drug discovery capabilities using the cloud computing platform of Amazon Web Services (@awscloud ), and Insilico Medicine also sells their.

RT @biogerontology: Turned 69 in h-years today and wanted to thank the team for their commitment to academic excellence and transparency.….

China’s AI drug discovery companies land huge deals with Big Pharma .

🚀 New platform capabilities: New Generative Model for Antibodies. This model utilizes a diffusion-based approach to generate antibody scaffolds before producing their sequences. Take a look at this latest video and see new frameworks, desired properties, ad more! 👇

Hong Kong Investment Corporation Limited Leads Delegation to Southeast Asia to Explore Regional Opportunities for Ecosystem Partners (August 2025).

Artificial intelligence is changing the game in drug discovery efforts. Here's how Boston-area biotechs are using it.

📣 Happening Today! Alex Zhavoronkov will discuss how his team uses #generativeAI and automation to streamline target discovery and advance #aging research. Topics to be covered:. -Identifying novel therapeutic targets and biomarkers with generative AI. -Integrating multiomics.

🚀 We are thrilled to announce our latest collaboration with Syngenta Group, a global leader in agricultural innovation, to explore the application of generative AI in crop science and sustainable agriculture. Through this collaboration, Insilico Medicine will bring the power of.

Insilico launched Life Star in 2022, a fully automated laboratory that performs target discovery, compound screening, precision medicine development and translational research. The lab uses Insilico’s PandaOmics to predict targets for specific diseases, enabling the automated lab.

Incredible collaboration! Thank you to the @SyngentaGroup 🤝.